Cabometyx Norway

Cabometyx in Europe

This is a promotional website intended for Healthcare Professionals in Norway

References (CABOMETYX® RCC)

  1. CABOMETYX® Summary of Product Characteristics.
  2. Jubb AM, Pham TQ, Hanby AM, et al. Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol. 2004;57(5):504-12.
  3. Nakagawa M, Emoto A, Hanada T, et al.Tubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor (VEGF) in renal cell carcinoma. Br J Urol. 1997;79(5):681-7.
  4. Gibney GT, Aziz SA, Camp RL, et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 2013;24:343–9.
  5. Rankin EB, Fuh KC, Castellini L, et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci U S A. 2014;111(37):13373-8.
  6. Zhou L, Liu XD, Sun M, et al.Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35(21):2687-97.
  7. Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35(6):591-7.
  8. Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94:115-25.
  9. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. New Eng J Med. 2015;373(19):1814-23.
  10. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.Lancet Oncol. 2016;17(7):917-27.
  11. Motzer RJ, Escudier B, Powles T, et al. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer. 2018;118(9):1176-78.
  12. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Feb 21. pii: mdz056. doi: 10.1093/annonc/mdz056. [Epub ahead of print]
  13. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma:N The 2019 update. Eur Urol. 2019;75(5):799–810.
  14. European Association of Urology guidelines on renal cell carcinoma. Available at https://uroweb.org/guideline/renal-cell-carcinoma. [Accessed July 16, 2019].
  15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Kidney Cancer. Version 4.2019 – April 2019.
© Ipsen Group 2020 Last updated on: October 2019. This site is published by Ipsen, which is solely responsible for the content. It is intended only for healthcare professionals from the Norway Healthcare professionals from outside the EU, as well as any non-healthcare professionals, are excluded from the intended audience. CBZ-ALL-001685

Welcome to Cabometyx.no website. This website is intended for Norway Healthcare professionals only.

Please confirm below that you are a registered healthcare professional.

I AM A NORWEGIAN HEALTHCARE PROFESSIONAL

I AM A EU HEALTHCARE PROFESSIONAL

I AM NOT A HEALTHCARE PROFESSIONAL